$INM News

InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript

Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline

UPDATE: InMed Pharmaceuticals To Merge With Mentari Therapeutics In All-Stock Deal Backed By $290M Private Placement, Combined Company Valued At $421.4M; InMed Shareholders to Own 1.51% Stake

InMed Pharmaceuticals To Merge With Mentari Therapeutics

InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Reports Preclinical Data Showing Reduced Brain Inflammation in Alzheimer's Models

InMed Pharmaceuticals Files Prospectus To Offer Up To $50M In Securities

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

On March 4, InMed Pharmaceuticals Confirmed And Approved The Decision To Wind Down BayMedica's Commercial Operations; BayMedica To Complete Wind Down Before Fiscal Year Ending June 30, 2026

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript

InMed Pharmaceuticals Expects Negative Impact On BayMedica From New Act H.R. 5371; Says BayMedica Evaluating Alternative Supply Chain Options

InMed Provides Update on BayMedica Commercial Business

Life Sciences Virtual Investor Forum Agenda Announced for December 11th

InMed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "CANNABINOID ANALOGS AND METHODS FOR THEIR PREPARATION (USEFUL FOR NEUROLOGICAL CONDITIONS, MOOD/BEHAVIOR DISORDERS, INFECTIONS, AND CANCERS)"